SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
BiologicsMolecular Targeted Therapeutics

PUBLISHER: Visiongain | PRODUCT CODE: 2151280

Cover Image

PUBLISHER: Visiongain | PRODUCT CODE: 2151280

Global Antibody Drug Conjugates Market Report 2026-2036

PUBLISHED:
PAGES: 431 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5872.50
PDF (Team License - Up to 6 Users)
USD 6952.50
PDF (Site License)
USD 8167.50
PDF (Enterprise License - Includes Free Datasets)
USD 10320.75

Add to Cart

Description

Table of Contents

List of Tables

The global ADC market is valued at US$18.42 billion in 2026 and is forecast to reach US$55.94 billion by 2036, at a CAGR of 11.8% over the forecast period, driven by the rising global cancer burden, accelerating R&D investment, novel target diversification beyond HER2, and expanding clinical adoption of ADC combination therapies.

Technological Innovation Driving Market Expansion

The ADC field is advancing rapidly across antibody engineering, linker chemistry, payload optimisation, and conjugation technologies, supporting development of increasingly differentiated next-generation candidates. Pipeline activity is expanding beyond established targets such as HER2 to include HER3, B7-H3, B7-H4, CLDN18.2, ROR1, and others, with bispecific ADCs targeting combinations such as EGFR/HER3 and CD3/CD7 progressing as approaches to tumour heterogeneity and treatment resistance.

Site-specific conjugation methods including THIOMAB, pClick, and AJICAP attach cytotoxic payloads at fixed antibody positions, giving more uniform drug-to-antibody ratios and reducing aggregation and off-target toxicity versus older random conjugation methods. Linker technology is advancing to remain stable during systemic circulation while enabling controlled payload release within tumour cells, with cleavable linkers responding to tumour-associated enzymes, acidic conditions, or intracellular reducing environments.

Innovation is also expanding beyond traditional tubulin inhibitors toward topoisomerase I inhibitors and novel payload classes, while biparatopic and bispecific ADC designs are improving tumour uptake and addressing uneven antigen expression. On 22 June 2026, Lonza and InduPro announced a licensing agreement combining InduPro's bispecific antibody capabilities with Lonza's GlycoConnect, HydraSpace, and linker-payload technologies for next-generation ADC development.

Trade & Supply Chain Dynamics

  • U.S. trade tariffs could place additional cost pressure on ADC companies sourcing specialised chemicals, linker-payload materials, manufacturing equipment, and other inputs through international supply chains.
  • The BIOSECURE Act and related U.S. biosecurity policy measures are increasing scrutiny around certain China-linked biotechnology service providers and supply chains, affecting ADC companies with outsourced antibody production, linker-payload synthesis, conjugation, and analytical testing relationships.
  • Chinese assets made up approximately US$11 billion, or 91%, of the US$12.1 billion in disclosed ADC licensing value in the first half of 2026, making continued access to Chinese ADC innovation commercially significant even as companies navigate biosecurity compliance.
  • Companies are responding by qualifying alternative CDMOs and technology partners in the U.S., Europe, and South Korea, though such transitions can increase technology-transfer requirements, validation costs, and development timelines.
  • Tariffs and biosecurity measures are more likely to reshape sourcing, manufacturing, and partnership strategies than reduce global ADC demand, which remains primarily driven by clinical need and treatment outcomes.

Commercial Impact

  • Supply chain diversification: Companies with significant exposure to affected China-linked suppliers are investing in qualifying alternative CDMOs and building regional manufacturing capability to reduce biosecurity and tariff risk
  • Licensing strategy complexity: The commercial importance of Chinese ADC innovation means companies must balance supply-chain and regulatory risk against continued access to a significant share of global ADC pipeline assets and licensing value
  • Capital concentration: Sustained investor interest in differentiated ADC platforms is supporting progression from discovery into clinical development, with large financing rounds completed by specialist developers in 2025 and 2026
  • Competitive positioning: Companies with site-specific conjugation capability, diversified payload platforms, and regionally resilient manufacturing are best positioned to compete across an expanding multi-target, multi-indication ADC landscape

Company Intelligence

The global ADC market is characterised by large pharmaceutical companies defending established franchises, specialist ADC developers advancing differentiated platforms, and a growing cohort of Chinese biotechnology companies contributing both innovation assets and development services.

Leading companies including Daiichi Sankyo, AstraZeneca, F. Hoffmann-La Roche, Gilead Sciences, and Pfizer are strengthening positions through next-generation ADC programme development, combination therapy approvals, and licensing of differentiated platforms.

Competition is increasingly defined by:

  • Next-generation conjugation platform capability including site-specific and bispecific ADC approaches
  • Novel target antigen breadth beyond HER2 across solid tumour and haematological indications
  • ADC combination therapy development with checkpoint inhibitors and targeted therapies
  • Regionally diversified CDMO and manufacturing relationships to manage biosecurity and tariff risk

This report analyses how competitive positioning is evolving across 20 leading companies, identifying where value is being created and how strategies are expected to shift over the forecast period.

Key Questions Answered

  • What is the projected size of the global ADC market by 2036?
  • Which product segments, payload types, and target antigens will drive the fastest growth?
  • How will next-generation conjugation, linker, and payload technologies reshape the competitive landscape?
  • What is the impact of U.S. trade tariffs and biosecurity policy on ADC sourcing, manufacturing, and licensing?
  • How are ADC combination therapies expanding clinical applications and market opportunity?
  • Who are the leading companies and how will their competitive positions evolve?

Report Scope and Data Coverage

  • Global ADC market analysis
  • Revenue forecasts to 2036
  • Segment-level modelling across product, payload type, linker type, target antigen, application, and end user
  • Regional and national market forecasts across five regions and 13 leading national markets
  • Competitive intelligence on 20 leading companies

Includes both quantitative forecasting and qualitative strategic analysis covering technology, competition, policy, and supply chain dynamics.

Segmentation Framework

By Product

  • Kadcyla
  • Enhertu
  • Adcetris
  • Padcev
  • Trodelvy
  • Polivy
  • Others (Elahere, Tivdak, Zynlonta, Blenrep, Mylotarg)

By Payload Type

  • Auristatins
  • Maytansinoids
  • Calicheamicin Derivatives
  • Topoisomerase I Inhibitors
  • Pyrrolobenzodiazepine (PBD) Dimers
  • Other Payload Type (Duocarmycin, Amanitins, Others)

By Linker Type

  • Cleavable Linkers
  • Non-Cleavable Linkers

By Target Antigen

  • CD30
  • HER2
  • CD22
  • CD33
  • Other Target Antigens (TROP2, Nectin-4, FRa, HER-3, B7-H3)

By Application

  • Blood Cancer
  • Breast Cancer
  • Autoimmune Diseases
  • Infectious Diseases
  • Other Applications (Lung, Gastric, Urothelial, Ovarian, Colorectal, Others)

By End User

  • Hospitals & Clinics
  • Speciality Centres
  • Others (Academic Institutions, Research Organisations, Clinical Trial Centres)

Geographic Coverage

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

Need industry data? Please contact us today.

Company Intelligence Coverage

This report includes detailed profiles of 20 leading companies, including:

  • Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • Daiichi Sankyo Company, Limited
  • AstraZeneca
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • ADC Therapeutics SA
  • The Servier Laboratories
  • BioNTech
  • Novartis AG
  • Johnson & Johnson
  • BeOne Medicines
  • Zymeworks Inc.
  • Innovent
  • Astellas Pharma Inc.
  • AbbVie Inc.
  • GSK plc
  • Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
  • Duality Biologics
  • Merck & Co., Inc.

Each profile includes:

  • Business overview
  • Financial and market positioning
  • Product and technology capabilities
  • Strategic outlook

Bespoke Intelligence & Customisation

Visiongain also provides tailored intelligence and advisory support aligned to specific client requirements.

This includes:

  • Custom market segmentation and forecasts
  • Competitive benchmarking and strategy analysis
  • Policy and regulatory impact assessment
  • Supply chain and CDMO sourcing intelligence
  • Scenario modelling including tariffs and biosecurity risk
Show more
Product Code: PHA1396

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Antibody Drug Conjugates Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Impact Analysis
    • 3.3.1 Market Driving Factors
      • 3.3.1.1 Growing Burden of Cancer
      • 3.3.1.2 Presence of Strong Pipeline Drugs in Phase III
      • 3.3.1.3 Increasing Breast Cancer Cases Driving Demand for Antibody-Drug Conjugates
      • 3.3.1.4 Increasing R&D Activities for Development of Novel Therapeutics
      • 3.3.1.5 Emerging Applications Beyond Oncology Expanding the Addressable Market
    • 3.3.2 Market Restraining Factors
      • 3.3.2.1 Complexities in Manufacturing
      • 3.3.2.2 Co-ordination Between Various Biopharmaceutical and CDMOs
      • 3.3.2.3 Antibody and Linker-Related Cytotoxin and Formulation Challenges
      • 3.3.2.4 Adverse Effects of Antibody-Drug Conjugates
    • 3.3.3 Market Opportunities
      • 3.3.3.1 Adoption of Combination Therapies
      • 3.3.3.2 Advancements in Antibody-Drug Conjugates (ADCs)
      • 3.3.3.3 Expanding Industry Investments and Collaborations in ADC Development
      • 3.3.3.4 Emerging Targets
  • 3.4 U.S. Tariffs: What's the Impact on Global Antibody Drug Conjugates Market?
    • 3.4.1 Overview
    • 3.4.2 V-Shaped Recovery Scenario
    • 3.4.3 Why V-Shaped Recovery?
      • 3.4.3.1 Impact from Tariffs
      • 3.4.3.2 Market Dynamics and Demand Recovery
      • 3.4.3.3 Policy and Funding Support
      • 3.4.3.4 Timeframe for Recovery
    • 3.4.4 U-Shaped Recovery Scenario
      • 3.4.4.1 Why U-Shaped Recovery?
      • 3.4.4.2 Impact from Tariffs
      • 3.4.4.3 Market Dynamics and Demand Recovery
      • 3.4.4.4 Policy and Funding Support
      • 3.4.4.5 Timeframe for Recovery
    • 3.4.5 L-Shaped Recovery Scenario
      • 3.4.5.1 Why L-Shaped Recovery?
      • 3.4.5.2 Impact from Tariffs
      • 3.4.5.3 Market Dynamics and Demand Recovery
      • 3.4.5.4 Policy and Funding Support
      • 3.4.5.5 Timeframe for Recovery
    • 3.4.6 What Strategic Considerations Should Clients Factor into Their Near-term (2026-2031) and Long-term (2026-2036) Planning?
    • 3.4.7 Impact of U.S. and China Trade War on Antibody Drug Conjugates Market
    • 3.4.8 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
  • 3.5 Porter's Five Forces Analysis
    • 3.5.1 Bargaining Power of Suppliers
    • 3.5.2 Bargaining Power of Buyers
    • 3.5.3 Competitive Rivalry
    • 3.5.4 Threat of Substitutes
    • 3.5.5 Threat of New Entrants
  • 3.6 PEST
    • 3.6.1 Political
    • 3.6.2 Economical
    • 3.6.3 Social
    • 3.6.4 Technological
  • 3.7 ADC at Crossroads of Innovation, China-Deals and Policy Shift
  • 3.8 Strategic Acquisitions Driving ADC Portfolio Growth
  • 3.9 Impact of Patent Expiry and Biosimilars on ADC Market
  • 3.10 Pricing and Reimbursement Landscape

4 Antibody Drug Conjugates Market Analysis by Product

  • 4.1 Key Findings
  • 4.2 Product Segment: Market Attractiveness Index
  • 4.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Product
  • 4.4 Kadcyla
    • 4.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 4.4.2 Market Share by Region, 2026 & 2036 (%)
  • 4.5 Enhertu
    • 4.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 4.5.2 Market Share by Region, 2026 & 2036 (%)
  • 4.6 Adcetris
    • 4.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 4.6.2 Market Share by Region, 2026 & 2036 (%)
  • 4.7 Padcev
    • 4.7.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 4.7.2 Market Share by Region, 2026 & 2036 (%)
  • 4.8 Trodelvy
    • 4.8.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 4.8.2 Market Share by Region, 2026 & 2036 (%)
  • 4.9 Polivy
    • 4.9.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 4.9.2 Market Share by Region, 2026 & 2036 (%)
  • 4.10 Others (Elahere, Tivdak, Zynlonta, Blenrep, Mylotarg)
    • 4.10.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 4.10.2 Market Share by Region, 2026 & 2036 (%)

5 Antibody Drug Conjugates Market Analysis by Payload Type

  • 5.1 Key Findings
  • 5.2 Payload Type Segment: Market Attractiveness Index
  • 5.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
  • 5.4 Auristatins
    • 5.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 5.4.2 Market Share by Region, 2026 & 2036 (%)
  • 5.5 Maytansinoids
    • 5.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 5.5.2 Market Share by Region, 2026 & 2036 (%)
  • 5.6 Calicheamicin Derivatives
    • 5.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 5.6.2 Market Share by Region, 2026 & 2036 (%)
  • 5.7 Topoisomerase I Inhibitors
    • 5.7.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 5.7.2 Market Share by Region, 2026 & 2036 (%)
  • 5.8 Pyrrolobenzodiazepine (PBD) Dimers
    • 5.8.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 5.8.2 Market Share by Region, 2026 & 2036 (%)
  • 5.9 Other Payload Type (Duocarmycin, Amanitins, Others)
    • 5.9.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 5.9.2 Market Share by Region, 2026 & 2036 (%)

6 Antibody Drug Conjugates Market Analysis by Linker Type

  • 6.1 Key Findings
  • 6.2 Linker Type Segment: Market Attractiveness Index
  • 6.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
  • 6.4 Cleavable Linkers
    • 6.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 6.4.2 Market Share by Region, 2026 & 2036 (%)
  • 6.5 Non-Cleavable Linkers
    • 6.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 6.5.2 Market Share by Region, 2026 & 2036 (%)

7 Antibody Drug Conjugates Market Analysis by Target Antigen

  • 7.1 Key Findings
  • 7.2 Target Antigen Segment: Market Attractiveness Index
  • 7.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
  • 7.4 CD30
    • 7.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 7.4.2 Market Share by Region, 2026 & 2036 (%)
  • 7.5 HER2
    • 7.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 7.5.2 Market Share by Region, 2026 & 2036 (%)
  • 7.6 CD22
    • 7.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 7.6.2 Market Share by Region, 2026 & 2036 (%)
  • 7.7 CD33
    • 7.7.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 7.7.2 Market Share by Region, 2026 & 2036 (%)
  • 7.8 Other Target Antigens (TROP2, Nectin-4, FRa, HER-3, B7-H3)
    • 7.8.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 7.8.2 Market Share by Region, 2026 & 2036 (%)

8 Antibody Drug Conjugates Market Analysis by Applications

  • 8.1 Key Findings
  • 8.2 Applications Segment: Market Attractiveness Index
  • 8.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
  • 8.4 Blood Cancer
    • 8.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 8.4.2 Market Share by Region, 2026 & 2036 (%)
  • 8.5 Breast Cancer
    • 8.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 8.5.2 Market Share by Region, 2026 & 2036 (%)
  • 8.6 Autoimmune Diseases
    • 8.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 8.6.2 Market Share by Region, 2026 & 2036 (%)
  • 8.7 Infectious Diseases
    • 8.7.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 8.7.2 Market Share by Region, 2026 & 2036 (%)
  • 8.8 Other Applications (Lung, Gastric, Urothelial, Ovarian, Colorectal, Others)
    • 8.8.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 8.8.2 Market Share by Region, 2026 & 2036 (%)

9 Antibody Drug Conjugates Market Analysis by End-users

  • 9.1 Key Findings
  • 9.2 End-users Segment: Market Attractiveness Index
  • 9.3 Antibody Drug Conjugates Market Size Estimation and Forecast by End-users
  • 9.4 Hospitals & Clinics
    • 9.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 9.4.2 Market Share by Region, 2026 & 2036 (%)
  • 9.5 Speciality Centres
    • 9.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 9.5.2 Market Share by Region, 2026 & 2036 (%)
  • 9.6 Others (Academic Institutions, Research Organisations, Clinical Trial Centres)
    • 9.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 9.6.2 Market Share by Region, 2026 & 2036 (%)

10 Antibody Drug Conjugates Market Analysis by Region

  • 10.1 Key Findings
  • 10.2 Regional Market Size Estimation and Forecast

11 North America Antibody Drug Conjugates Market Analysis

  • 11.1 Key Findings
  • 11.2 North America Antibody Drug Conjugates Market Attractiveness Index
  • 11.3 North America Antibody Drug Conjugates Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 11.4 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Country
  • 11.5 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Product
  • 11.6 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
  • 11.7 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
  • 11.8 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
  • 11.9 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
  • 11.10 North America Antibody Drug Conjugates Market Size Estimation and Forecast by End-users
  • 11.11 U.S. Antibody Drug Conjugates Market Analysis
  • 11.12 Canada Antibody Drug Conjugates Market Analysis

12 Europe Antibody Drug Conjugates Market Analysis

  • 12.1 Key Findings
  • 12.2 Europe Antibody Drug Conjugates Market Attractiveness Index
  • 12.3 Europe Antibody Drug Conjugates Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 12.4 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Country
  • 12.5 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Product
  • 12.6 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
  • 12.7 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
  • 12.8 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
  • 12.9 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
  • 12.10 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by End-users
  • 12.11 Germany Antibody Drug Conjugates Market Analysis
  • 12.12 UK Antibody Drug Conjugates Market Analysis
  • 12.13 France Antibody Drug Conjugates Market Analysis
  • 12.14 Italy Antibody Drug Conjugates Market Analysis
  • 12.15 Rest of Europe Antibody Drug Conjugates Market Analysis

13 Asia Pacific Antibody Drug Conjugates Market Analysis

  • 13.1 Key Findings
  • 13.2 Asia Pacific Antibody Drug Conjugates Market Attractiveness Index
  • 13.3 Asia Pacific Antibody Drug Conjugates Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 13.4 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Country
  • 13.5 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Product
  • 13.6 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
  • 13.7 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
  • 13.8 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
  • 13.9 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
  • 13.10 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by End-users
  • 13.11 Japan Antibody Drug Conjugates Market Analysis
  • 13.12 China Antibody Drug Conjugates Market Analysis
  • 13.13 India Antibody Drug Conjugates Market Analysis
  • 13.14 Rest of Asia Pacific Antibody Drug Conjugates Market Analysis

14 Latin America Antibody Drug Conjugates Market Analysis

  • 14.1 Key Findings
  • 14.2 Latin America Antibody Drug Conjugates Market Attractiveness Index
  • 14.3 Latin America Antibody Drug Conjugates Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 14.4 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Country
  • 14.5 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Product
  • 14.6 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
  • 14.7 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
  • 14.8 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
  • 14.9 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
  • 14.10 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by End-users
  • 14.11 Brazil Antibody Drug Conjugates Market Analysis
  • 14.12 Mexico Antibody Drug Conjugates Market Analysis
  • 14.13 Rest of Latin America Antibody Drug Conjugates Market Analysis

15 MEA Antibody Drug Conjugates Market Analysis

  • 15.1 Key Findings
  • 15.2 MEA Antibody Drug Conjugates Market Attractiveness Index
  • 15.3 MEA Antibody Drug Conjugates Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 15.4 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Country
  • 15.5 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Product
  • 15.6 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
  • 15.7 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
  • 15.8 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
  • 15.9 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
  • 15.10 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by End-users
  • 15.11 GCC Antibody Drug Conjugates Market Analysis
  • 15.12 South Africa Antibody Drug Conjugates Market Analysis
  • 15.13 Rest of MEA Antibody Drug Conjugates Market Analysis

16 Company Profiles

  • 16.1 F. Hoffmann-La Roche Ltd
    • 16.1.1 Company Snapshot
    • 16.1.2 Company Overview
    • 16.1.3 Financial Analysis
      • 16.1.3.1 Net Revenue, 2022-2025
      • 16.1.3.2 R&D, 2022-2025
      • 16.1.3.3 Business Segment Market Shares, 2025
    • 16.1.4 Product Benchmarking
    • 16.1.5 Strategic Outlook
  • 16.2 Gilead Sciences, Inc.
    • 16.2.1 Company Snapshot
    • 16.2.2 Company Overview
    • 16.2.3 Financial Analysis
      • 16.2.3.1 Net Revenue, 2022-2025
      • 16.2.3.2 R&D, 2022-2025
      • 16.2.3.3 Regional Market Shares, 2025
      • 16.2.3.4 Business Segment Market Shares, 2025
    • 16.2.4 Product Benchmarking
    • 16.2.5 Strategic Outlook
  • 16.3 Daiichi Sankyo Company, Limited
    • 16.3.1 Company Snapshot
    • 16.3.2 Company Overview
    • 16.3.3 Product Benchmarking
    • 16.3.4 Strategic Outlook
  • 16.4 AstraZeneca
    • 16.4.1 Company Snapshot
    • 16.4.2 Company Overview
    • 16.4.3 Financial Analysis
      • 16.4.3.1 Net Revenue, 2022-2025
      • 16.4.3.2 R&D, 2022-2025
      • 16.4.3.3 Regional Market Shares, 2025
      • 16.4.3.4 Business Segment Market Shares, 2025
    • 16.4.4 Product Benchmarking
    • 16.4.5 Strategic Outlook
  • 16.5 Pfizer Inc.
    • 16.5.1 Company Snapshot
    • 16.5.2 Company Overview
    • 16.5.3 Financial Analysis
      • 16.5.3.1 Net Revenue, 2022-2025
      • 16.5.3.2 R&D, 2022-2025
      • 16.5.3.3 Regional Market Shares, 2025
      • 16.5.3.4 Business Segment Market Shares, 2025
    • 16.5.4 Product Benchmarking
    • 16.5.5 Strategic Outlook
  • 16.6 Takeda Pharmaceutical Company Limited
    • 16.6.1 Company Snapshot
    • 16.6.2 Company Overview
    • 16.6.3 Financial Analysis
      • 16.6.3.1 Net Revenue, 2022-2025
      • 16.6.3.2 R&D, 2022-2025
      • 16.6.3.3 Regional Market Shares, 2025
    • 16.6.4 Product Benchmarking
    • 16.6.5 Strategic Outlook
  • 16.7 ADC Therapeutics SA
    • 16.7.1 Company Snapshot
    • 16.7.2 Company Overview
    • 16.7.3 Financial Analysis
      • 16.7.3.1 Net Revenue, 2022-2025
      • 16.7.3.2 R&D, 2022-2025
    • 16.7.4 Product Benchmarking
    • 16.7.5 Strategic Outlook
  • 16.8 The Servier Laboratories
    • 16.8.1 Company Snapshot
    • 16.8.2 Company Overview
    • 16.8.3 Product Benchmarking
    • 16.8.4 Strategic Outlook
  • 16.9 BioNTech
    • 16.9.1 Company Snapshot
    • 16.9.2 Company Overview
    • 16.9.3 Financial Analysis
      • 16.9.3.1 Net Revenue, 2022-2025
      • 16.9.3.2 R&D, 2022-2025
    • 16.9.4 Product Benchmarking
    • 16.9.5 Strategic Outlook
  • 16.10 Novartis AG
    • 16.10.1 Company Snapshot
    • 16.10.2 Company Overview
    • 16.10.3 Financial Analysis
      • 16.10.3.1 Net Revenue, 2022-2025
      • 16.10.3.2 R&D, 2022-2025
      • 16.10.3.3 Regional Market Shares, 2025
      • 16.10.3.4 Business Segment Market Shares, 2025
    • 16.10.4 Product Benchmarking
    • 16.10.5 Strategic Outlook
  • 16.11 Johnson & Johnson
    • 16.11.1 Company Snapshot
    • 16.11.2 Company Overview
    • 16.11.3 Financial Analysis
      • 16.11.3.1 Net Revenue, 2022-2025
      • 16.11.3.2 R&D, 2022-2025
      • 16.11.3.3 Regional Market Shares, 2025
      • 16.11.3.4 Business Segment Market Shares, 2025
    • 16.11.4 Product Benchmarking
  • 16.12 BeOne Medicines
    • 16.12.1 Company Snapshot
    • 16.12.2 Company Overview
    • 16.12.3 Product Benchmarking
    • 16.12.4 Strategic Outlook
  • 16.13 Zymeworks Inc.
    • 16.13.1 Company Snapshot
    • 16.13.2 Company Overview
    • 16.13.3 Product Benchmarking
    • 16.13.4 Strategic Outlook
  • 16.14 Innovent
    • 16.14.1 Company Snapshot
    • 16.14.2 Company Overview
    • 16.14.3 Product Benchmarking
    • 16.14.4 Strategic Outlook
  • 16.15 Astellas Pharma Inc.
    • 16.15.1 Company Snapshot
    • 16.15.2 Company Overview
    • 16.15.3 Financial Analysis
      • 16.15.3.1 Net Revenue, 2022-2025
      • 16.15.3.2 R&D, 2022-2025
      • 16.15.3.3 Regional Market Shares, 2025
      • 16.15.3.4 Business Segment Market Shares, 2025
    • 16.15.4 Product Benchmarking
    • 16.15.5 Strategic Outlook
  • 16.16 AbbVie Inc.
    • 16.16.1 Company Snapshot
    • 16.16.2 Company Overview
    • 16.16.3 Financial Analysis
      • 16.16.3.1 Net Revenue, 2022-2025
      • 16.16.3.2 R&D, 2022-2025
      • 16.16.3.3 Regional Market Shares, 2025
      • 16.16.3.4 Business Segment Market Shares, 2025
    • 16.16.4 Product Benchmarking
    • 16.16.5 Strategic Outlook
  • 16.17 GSK plc
    • 16.17.1 Company Snapshot
    • 16.17.2 Company Overview
    • 16.17.3 Financial Analysis
      • 16.17.3.1 Net Revenue, 2022-2025
      • 16.17.3.2 R&D, 2022-2025
      • 16.17.3.3 Regional Market Shares, 2025
      • 16.17.3.4 Business Segment Market Shares, 2025
    • 16.17.4 Product Benchmarking
    • 16.17.5 Strategic Outlook
  • 16.18 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    • 16.18.1 Company Snapshot
    • 16.18.2 Company Overview
    • 16.18.3 Product Benchmarking
    • 16.18.4 Strategic Outlook
  • 16.19 Duality Biologics
    • 16.19.1 Company Snapshot
    • 16.19.2 Company Overview
    • 16.19.3 Financial Analysis
      • 16.19.3.1 Net Revenue, 2022-2025
    • 16.19.4 Product Benchmarking
    • 16.19.5 Strategic Outlook
  • 16.20 Merck & Co., Inc.
    • 16.20.1 Company Snapshot
    • 16.20.2 Company Overview
    • 16.20.3 Financial Analysis
      • 16.20.3.1 Net Revenue, 2022-2025
      • 16.20.3.2 R&D, 2022-2025
      • 16.20.3.3 Regional Market Shares, 2025
    • 16.20.4 Product Benchmarking

17 Conclusion and Recommendations

  • 17.1 Concluding Remarks from Visiongain
  • 17.2 Recommendations for Market Players
Show more
Product Code: PHA1396

List of Tables

  • Table 1 Antibody Drug Conjugates Market Snapshot, 2026 & 2036 (US$ Billion, CAGR %)
  • Table 2 Antibody Drug Conjugates in Phase III
  • Table 3 Antibody Drug Conjugates Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): V-Shaped Recovery
  • Table 4 Antibody Drug Conjugates Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): U-Shaped Recovery
  • Table 5 Antibody Drug Conjugates Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): L-Shaped Recovery
  • Table 6 Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 7 Kadcyla Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 8 Enhertu Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 9 Adcetris Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 10 Padcev Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 11 Trodelvy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 12 Polivy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 13 Other Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 14 Auristatins Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 15 Maytansinoids Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 16 Calicheamicin Derivatives Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 17 Topoisomerase I Inhibitors Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 18 Pyrrolobenzodiazepine (PBD) Dimers Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 19 Other Payload Type Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 20 Antibody Drug Conjugates Market Forecast by Technology, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 21 Cleavable Linkers Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 22 Non-Cleavable Linkers Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 23 Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 24 CD30 Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 25 HER2 Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 26 CD22 Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 27 CD33 Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 28 Other Target Antigens Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 29 Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 30 Blood Cancer Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 31 Breast Cancer Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 32 Autoimmune Diseases Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 33 Infectious Diseases Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 34 Other Applications Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 35 Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 36 Hospitals & Clinics Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 37 Speciality Centres Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 38 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 39 Antibody Drug Conjugates Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 40 North America Antibody Drug Conjugates Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 41 North America Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 42 North America Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 43 North America Antibody Drug Conjugates Market Forecast by Technology, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 44 North America Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 45 North America Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 46 North America Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 47 U.S. Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 48 Canada Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 49 Europe Antibody Drug Conjugates Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 50 Europe Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 51 Europe Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 52 Europe Antibody Drug Conjugates Market Forecast by Technology, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 53 Europe Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 54 Europe Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 55 Europe Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 56 Germany Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 57 UK Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 58 France Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 59 Italy Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 60 Rest of Europe Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 61 Asia Pacific Antibody Drug Conjugates Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 62 Asia Pacific Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 63 Asia Pacific Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 64 Asia Pacific Antibody Drug Conjugates Market Forecast by Technology, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 65 Asia Pacific Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 66 Asia Pacific Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 67 Asia Pacific Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 68 Japan Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 69 India Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 70 India Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 71 Rest of Asia Pacific Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 72 Latin America Antibody Drug Conjugates Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 73 Latin America Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 74 Latin America Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 75 Latin America Antibody Drug Conjugates Market Forecast by Technology, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 76 Latin America Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 77 Latin America Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 78 Latin America Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 79 Brazil Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 80 Mexico Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 81 Rest of Latin America Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 82 MEA Antibody Drug Conjugates Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 83 MEA Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 84 MEA Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 85 MEA Antibody Drug Conjugates Market Forecast by Technology, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 86 MEA Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 87 MEA Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 88 MEA Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 89 GCC Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 90 South Africa Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 91 Rest of MEA Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 92 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 93 F. Hoffmann-La Roche Ltd: Product Benchmarking
  • Table 94 F. Hoffmann-La Roche Ltd: Strategic Outlook
  • Table 95 Gilead Sciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 96 Gilead Sciences, Inc.: Product Benchmarking
  • Table 97 Gilead Sciences, Inc.: Strategic Outlook
  • Table 98 DAIICHI SANKYO COMPANY, LIMITED: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 99 DAIICHI SANKYO COMPANY, LIMITED: Product Benchmarking
  • Table 100 DAIICHI SANKYO COMPANY, LIMITED: Strategic Outlook
  • Table 101 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 102 AstraZeneca: Product Benchmarking
  • Table 103 AstraZeneca: Strategic Outlook
  • Table 104 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 105 Pfizer Inc.: Product Benchmarking
  • Table 106 Pfizer Inc.: Strategic Outlook
  • Table 107 Takeda Pharmaceutical Company Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 108 Takeda Pharmaceutical Company Limited: Product Benchmarking
  • Table 109 Takeda Pharmaceutical Company Limited: Strategic Outlook
  • Table 110 ADC Therapeutics SA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 111 ADC Therapeutics SA: Product Benchmarking
  • Table 112 ADC Therapeutics SA: Strategic Outlook
  • Table 113 The Servier Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 114 The Servier Laboratories: Product Benchmarking
  • Table 115 The Servier Laboratories: Strategic Outlook
  • Table 116 BioNTech: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 117 BioNTech: Product Benchmarking
  • Table 118 BioNTech: Strategic Outlook
  • Table 119 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 120 Novartis AG: Product Benchmarking
  • Table 121 Novartis AG: Strategic Outlook
  • Table 122 Johnson & Johnson: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 123 Johnson & Johnson: Product Benchmarking
  • Table 124 BeOne Medicines: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 125 BeOne Medicines: Product Benchmarking
  • Table 126 BeOne Medicines: Strategic Outlook
  • Table 127 Zymeworks Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 128 Zymeworks Inc.: Product Benchmarking
  • Table 129 Zymeworks Inc.: Strategic Outlook
  • Table 130 Innovent: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 131 Innovent: Product Benchmarking
  • Table 132 Innovent: Strategic Outlook
  • Table 133 Astellas Pharma Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 134 Astellas Pharma Inc.: Product Benchmarking
  • Table 135 Astellas Pharma Inc.: Strategic Outlook
  • Table 136 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 137 AbbVie Inc.: Product Benchmarking
  • Table 138 AbbVie Inc.: Strategic Outlook
  • Table 139 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 140 GSK plc: Product Benchmarking
  • Table 141 GSK plc: Strategic Outlook
  • Table 142 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 143 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.: Product Benchmarking
  • Table 144 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.: Strategic Outlook
  • Table 145 Duality Biologics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 146 Duality Biologics: Product Benchmarking
  • Table 147 Duality Biologics: Strategic Outlook
  • Table 148 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 149 Merck & Co., Inc.: Product Benchmarking

List of Figures

  • Figure 1 Antibody Drug Conjugates Market Segmentation
  • Figure 2 Antibody Drug Conjugates Market: Research Methodology
  • Figure 3 Approved Antibody Drug Conjugates, Global Sales in US$, 2024 to 2036
  • Figure 4 Antibody Drug Conjugates Market: Research Methodology
  • Figure 5 Antibody Drug Conjugates Market by Product: Market Attractiveness Index
  • Figure 6 Antibody Drug Conjugates Market by Payload Type: Market Attractiveness Index
  • Figure 7 Antibody Drug Conjugates Market by Linker Type: Market Attractiveness Index
  • Figure 8 Antibody Drug Conjugates Market by Target Antigen: Market Attractiveness Index
  • Figure 9 Antibody Drug Conjugates Market by Applications: Market Attractiveness Index
  • Figure 10 Antibody Drug Conjugates Market by End-users: Market Attractiveness Index
  • Figure 11 Antibody Drug Conjugates Market Attractiveness Index by Region
  • Figure 12 Antibody Drug Conjugates Market: Market Dynamics
  • Figure 13 Antibody Drug Conjugates Market: Impact Analysis
  • Figure 14 Antibody Drug Conjugates Market: Generalised Process Flow for ADCs
  • Figure 15 Antibody Drug Conjugates Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: V-Shaped Recovery Scenario
  • Figure 16 Antibody Drug Conjugates Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: U-Shaped Recovery Scenario
  • Figure 17 Antibody Drug Conjugates Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: L-Shaped Recovery Scenario
  • Figure 18 Short Term & Long-Term Planning
  • Figure 19 Impact of U.S. and China Trade War
  • Figure 20 Most Impacted Countries
  • Figure 21 Antibody Drug Conjugates Market: Porter's Five Forces Analysis
  • Figure 22 Antibody Drug Conjugates Market: PEST Analysis
  • Figure 23 Antibody Drug Conjugates Market Attractiveness Index by Product
  • Figure 24 Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR %)
  • Figure 25 Antibody Drug Conjugates Market Share Forecast by Product, 2026, 2031, 2036 (%)
  • Figure 26 Kadcyla Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 27 Kadcyla Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 28 Enhertu Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 29 Enhertu Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 30 Adcetris Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 31 Adcetris Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 32 Padcev Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 33 Padcev Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 34 Trodelvy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 35 Trodelvy Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 36 Polivy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 37 Polivy Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 38 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 39 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 40 Antibody Drug Conjugates Market Attractiveness Index by Payload Type
  • Figure 41 Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 42 Antibody Drug Conjugates Market Share Forecast by Payload Type, 2026, 2031, 2036 (%)
  • Figure 43 Auristatins Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 44 Auristatins Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 45 Maytansinoids Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 46 Maytansinoids Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 47 Calicheamicin Derivatives Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 48 Calicheamicin Derivatives Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 49 Topoisomerase I Inhibitors Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 50 Topoisomerase I Inhibitors Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 51 Pyrrolobenzodiazepine (PBD) Dimers Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 52 Pyrrolobenzodiazepine (PBD) Dimers Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 53 Other Payload Type Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 54 Other Payload Type Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 55 Antibody Drug Conjugates Market Attractiveness Index by Linker Type
  • Figure 56 Antibody Drug Conjugates Market Forecast by Linker Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 57 Antibody Drug Conjugates Market Share Forecast by Linker Type, 2026, 2031, 2036 (%)
  • Figure 58 Cleavable Linkers Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 59 Cleavable Linkers Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 60 Non-Cleavable Linkers Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 61 Non-Cleavable Linkers Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 62 Antibody Drug Conjugates Market Attractiveness Index by Target Antigen
  • Figure 63 Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR %)
  • Figure 64 Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2026, 2031, 2036 (%)
  • Figure 65 CD30 Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 66 CD30 Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 67 HER2 Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 68 HER2 Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 69 CD22 Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 70 CD22 Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 71 CD33 Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 72 CD33 Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 73 Other Target Antigens Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 74 Other Target Antigens Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 75 Antibody Drug Conjugates Market Attractiveness Index by Applications
  • Figure 76 Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR %)
  • Figure 77 Antibody Drug Conjugates Market Share Forecast by Applications, 2026, 2031, 2036 (%)
  • Figure 78 Blood Cancer Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 79 Blood Cancer Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 80 Breast Cancer Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 81 Breast Cancer Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 82 Autoimmune Diseases Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 83 Autoimmune Diseases Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 84 Infectious Diseases Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 85 Infectious Diseases Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 86 Other Applications Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 87 Other Applications Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 88 Antibody Drug Conjugates Market Attractiveness Index by End-users
  • Figure 89 Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
  • Figure 90 Antibody Drug Conjugates Market Share Forecast by End-users, 2026, 2031, 2036 (%)
  • Figure 91 Hospitals & Clinics Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 92 Hospitals & Clinics Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 93 Speciality Centres Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 94 Speciality Centres Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 95 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 96 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 97 Antibody Drug Conjugates Market Forecast by Region 2026, 2031, 2036 (Revenue, CAGR%)
  • Figure 98 Antibody Drug Conjugates Market Share Forecast by Region 2026, 2031, 2036 (%)
  • Figure 99 Antibody Drug Conjugates Market by Region, 2026-2036 (US$ Mn)
  • Figure 100 North America Antibody Drug Conjugates Market Attractiveness Index
  • Figure 101 North America Antibody Drug Conjugates Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 102 North America Antibody Drug Conjugates Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 103 North America Antibody Drug Conjugates Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 104 North America Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR %)
  • Figure 105 North America Antibody Drug Conjugates Market Share Forecast by Product, 2026 & 2036 (%)
  • Figure 106 North America Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 107 North America Antibody Drug Conjugates Market Share Forecast by Payload Type, 2026 & 2036 (%)
  • Figure 108 North America Antibody Drug Conjugates Market Forecast by Linker Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 109 North America Antibody Drug Conjugates Market Share Forecast by Linker Type, 2026 & 2036 (%)
  • Figure 110 North America Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR %)
  • Figure 111 North America Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2026 & 2036 (%)
  • Figure 112 North America Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR %)
  • Figure 113 North America Antibody Drug Conjugates Market Share Forecast by Applications, 2026 & 2036 (%)
  • Figure 114 North America Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
  • Figure 115 North America Antibody Drug Conjugates Market Share Forecast by End-users, 2026 & 2036 (%)
  • Figure 116 U.S. Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 117 Canada Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 118 Europe Antibody Drug Conjugates Market Attractiveness Index
  • Figure 119 Europe Antibody Drug Conjugates Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 120 Europe Antibody Drug Conjugates Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 121 Europe Antibody Drug Conjugates Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 122 Europe Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR %)
  • Figure 123 Europe Antibody Drug Conjugates Market Share Forecast by Product, 2026 & 2036 (%)
  • Figure 124 Europe Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 125 Europe Antibody Drug Conjugates Market Share Forecast by Payload Type, 2026 & 2036 (%)
  • Figure 126 Europe Antibody Drug Conjugates Market Forecast by Linker Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 127 Europe Antibody Drug Conjugates Market Share Forecast by Linker Type, 2026 & 2036 (%)
  • Figure 128 Europe Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR %)
  • Figure 129 Europe Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2026 & 2036 (%)
  • Figure 130 Europe Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR %)
  • Figure 131 Europe Antibody Drug Conjugates Market Share Forecast by Applications, 2026 & 2036 (%)
  • Figure 132 Europe Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
  • Figure 133 Europe Antibody Drug Conjugates Market Share Forecast by End-users, 2026 & 2036 (%)
  • Figure 134 Germany Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 135 UK Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 136 France Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 137 Italy Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 138 Rest of Europe Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 139 Asia Pacific Antibody Drug Conjugates Market Attractiveness Index
  • Figure 140 Asia Pacific Antibody Drug Conjugates Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 141 Asia Pacific Antibody Drug Conjugates Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 142 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 143 Asia Pacific Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR %)
  • Figure 144 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Product, 2026 & 2036 (%)
  • Figure 145 Asia Pacific Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 146 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Payload Type, 2026 & 2036 (%)
  • Figure 147 Asia Pacific Antibody Drug Conjugates Market Forecast by Linker Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 148 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Linker Type, 2026 & 2036 (%)
  • Figure 149 Asia Pacific Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR %)
  • Figure 150 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2026 & 2036 (%)
  • Figure 151 Asia Pacific Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR %)
  • Figure 152 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Applications, 2026 & 2036 (%)
  • Figure 153 Asia Pacific Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
  • Figure 154 Asia Pacific Antibody Drug Conjugates Market Share Forecast by End-users, 2026 & 2036 (%)
  • Figure 155 Japan Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 156 China Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 157 India Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 158 Rest of Asia Pacific Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 159 Latin America Antibody Drug Conjugates Market Attractiveness Index
  • Figure 160 Latin America Antibody Drug Conjugates Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 161 Latin America Antibody Drug Conjugates Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 162 Latin America Antibody Drug Conjugates Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 163 Latin America Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR %)
  • Figure 164 Latin America Antibody Drug Conjugates Market Share Forecast by Product, 2026 & 2036 (%)
  • Figure 165 Latin America Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 166 Latin America Antibody Drug Conjugates Market Share Forecast by Payload Type, 2026 & 2036 (%)
  • Figure 167 Latin America Antibody Drug Conjugates Market Forecast by Linker Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 168 Latin America Antibody Drug Conjugates Market Share Forecast by Linker Type, 2026 & 2036 (%)
  • Figure 169 Latin America Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR %)
  • Figure 170 Latin America Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2026 & 2036 (%)
  • Figure 171 Latin America Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR %)
  • Figure 172 Latin America Antibody Drug Conjugates Market Share Forecast by Applications, 2026 & 2036 (%)
  • Figure 173 Latin America Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
  • Figure 174 Latin America Antibody Drug Conjugates Market Share Forecast by End-users, 2026 & 2036 (%)
  • Figure 175 Brazil Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 176 Mexico Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 177 Rest of Latin America Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 178 MEA Antibody Drug Conjugates Market Attractiveness Index
  • Figure 179 MEA Antibody Drug Conjugates Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 180 MEA Antibody Drug Conjugates Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 181 MEA Antibody Drug Conjugates Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 182 MEA Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR %)
  • Figure 183 MEA Antibody Drug Conjugates Market Share Forecast by Product, 2026 & 2036 (%)
  • Figure 184 MEA Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 185 MEA Antibody Drug Conjugates Market Share Forecast by Payload Type, 2026 & 2036 (%)
  • Figure 186 MEA Antibody Drug Conjugates Market Forecast by Linker Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 187 MEA Antibody Drug Conjugates Market Share Forecast by Linker Type, 2026 & 2036 (%)
  • Figure 188 MEA Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR %)
  • Figure 189 MEA Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2026 & 2036 (%)
  • Figure 190 MEA Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR %)
  • Figure 191 MEA Antibody Drug Conjugates Market Share Forecast by Applications, 2026 & 2036 (%)
  • Figure 192 MEA Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
  • Figure 193 MEA Antibody Drug Conjugates Market Share Forecast by End-users, 2026 & 2036 (%)
  • Figure 194 GCC Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 195 South Africa Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 196 Rest of MEA Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 197 F. Hoffmann-La Roche Ltd: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 198 F. Hoffmann-La Roche Ltd: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 199 F. Hoffmann-La Roche Ltd: Business Segment Market Shares (%), 2025
  • Figure 200 Gilead Sciences, Inc.: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 201 Gilead Sciences, Inc.: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 202 Gilead Sciences, Inc.: Regional Market Shares (%), 2025
  • Figure 203 Gilead Sciences, Inc.: Business Segment Market Shares (%), 2025
  • Figure 204 AstraZeneca: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 205 AstraZeneca: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 206 AstraZeneca: R
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!